Kim J, Kim J, Ko E, Kim J, Im B, Kim G
Cancers (Basel). 2025; 17(5).
PMID: 40075741
PMC: 11898427.
DOI: 10.3390/cancers17050894.
Masthoff M, Irle M, Kaldewey D, Rennebaum F, Morgul H, Pohler G
Cancers (Basel). 2025; 17(5).
PMID: 40075740
PMC: 11899091.
DOI: 10.3390/cancers17050893.
Samanta T, Park J, Kaipparettu B
Cancers (Basel). 2025; 17(5).
PMID: 40075691
PMC: 11898429.
DOI: 10.3390/cancers17050844.
Zhou P, Huang R, Wang H, Yang J, Peng J, Fu Z
World J Gastrointest Surg. 2025; 17(2):98578.
PMID: 40061977
PMC: 11886001.
DOI: 10.4240/wjgs.v17.i2.98578.
Wei X, Cao W, Wang S, Zhang Y, Gao Z, Wang S
Int J Nanomedicine. 2025; 20:2623-2643.
PMID: 40061885
PMC: 11887507.
DOI: 10.2147/IJN.S509409.
Survival Benefits of Transarterial Chemoembolization Plus Ablation Therapy in Patients With Intermediate or Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Dai J, Ding Y, Zheng Q, Zhao G, Zou L, Zhao J
Cancer Manag Res. 2025; 17:483-497.
PMID: 40060703
PMC: 11890005.
DOI: 10.2147/CMAR.S511364.
Transcriptomics, lipidomics, and single-nucleus RNA sequencing integration: exploring sphingolipids in MASH-HCC progression.
Zeng J, Way G, Wu N, Jiang X, Tai Y, Zhao D
Cell Biosci. 2025; 15(1):34.
PMID: 40057751
PMC: 11890728.
DOI: 10.1186/s13578-025-01362-5.
Radiofrequency ablation versus stereotactic body radiotherapy for recurrent hepatocellular carcinoma: a multicenter, propensity score matching analysis.
Ma Z, Lin X, Liu F, Zhang J, Yan M, Song X
BMC Cancer. 2025; 25(1):424.
PMID: 40057688
PMC: 11889815.
DOI: 10.1186/s12885-025-13800-1.
5-Hydroxymethylcytosine modifications in circulating cell-free DNA: frontiers of cancer detection, monitoring, and prognostic evaluation.
Song D, Zhang Z, Zheng J, Zhang W, Cai J
Biomark Res. 2025; 13(1):39.
PMID: 40055844
PMC: 11887266.
DOI: 10.1186/s40364-025-00751-9.
Validation of an albumin-indocyanine green-based China liver cancer staging system to evaluating resectable hepatocellular carcinoma patients and comparison with the Child-Pugh-based China liver cancer staging system.
Chen M, Ren C, Wang M, Yu M, Wu B, Zhuang B
Front Oncol. 2025; 15:1450333.
PMID: 40052123
PMC: 11882571.
DOI: 10.3389/fonc.2025.1450333.
Development of a prognostic model for hepatocellular carcinoma based on microvascular invasion characteristic genes by spatial transcriptomics sequencing.
Mu X, Pan L, Wang X, Liu C, Li Y, Cai Y
Front Immunol. 2025; 16:1529569.
PMID: 40051627
PMC: 11882567.
DOI: 10.3389/fimmu.2025.1529569.
Des-γ-carboxy Prothrombin in hepatocellular carcinoma post-operative recurrence risk evaluation.
Pan X, Zhou Y, Li Z, Guo P, Zeng J, Dong X
Commun Med (Lond). 2025; 5(1):65.
PMID: 40050645
PMC: 11885828.
DOI: 10.1038/s43856-025-00784-z.
Pilot study of an arterial enhancement fraction-based model for progression prediction in HCC undergoing chemoembolization.
Chai B, Xiang D, Zhou G, Zheng C
Front Oncol. 2025; 15:1489450.
PMID: 40046631
PMC: 11879821.
DOI: 10.3389/fonc.2025.1489450.
Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinoma.
Shiode Y, Kodama T, Sato Y, Takahashi R, Matsumae T, Shirai K
Biomark Res. 2025; 13(1):37.
PMID: 40038575
PMC: 11877696.
DOI: 10.1186/s40364-025-00752-8.
Development and validation of an ultrasound-based interpretable machine learning model for the classification of ≤3 cm hepatocellular carcinoma: a multicentre retrospective diagnostic study.
Du Z, Fan F, Ma J, Liu J, Yan X, Chen X
EClinicalMedicine. 2025; 81:103098.
PMID: 40034568
PMC: 11872562.
DOI: 10.1016/j.eclinm.2025.103098.
National Survey of Real-World Australian Treatment Patterns for Patients With Very-Early-To Intermediate-Stage Hepatocellular Carcinoma.
Roberts S, Majeed A, Rasaratnam K, Olynyk J, Shackel N, Wood M
Cancer Med. 2025; 14(5):e70722.
PMID: 40018806
PMC: 11868786.
DOI: 10.1002/cam4.70722.
Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma.
Wakamatsu R, Nakayama M, Wakamatsu A, Yamashita Y, Suto H, Katsuragawa M
In Vivo. 2025; 39(2):988-999.
PMID: 40010999
PMC: 11884448.
DOI: 10.21873/invivo.13904.
Hepatitis C Virus Resistance-Associated Substitutions in Mexico.
Jose-Abrego A, Laguna-Meraz S, Roman S, Mariscal-Martinez I, Panduro A
Viruses. 2025; 17(2).
PMID: 40006924
PMC: 11860613.
DOI: 10.3390/v17020169.
Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.
Bourganou M, Chondrogianni M, Kyrou I, Flessa C, Chatzigeorgiou A, Oikonomou E
Int J Mol Sci. 2025; 26(4).
PMID: 40004054
PMC: 11855544.
DOI: 10.3390/ijms26041589.
N-Ammonia PET-CT for Evaluating Response to Antiangiogenic Therapy and Prognosis in Patients with Advanced Hepatocellular Carcinoma: A Pilot Study.
Scolozzi V, Nicoletti A, Capotosti A, Ponziani F, Taralli S, Genco E
Cancers (Basel). 2025; 17(4).
PMID: 40002251
PMC: 11853641.
DOI: 10.3390/cancers17040656.